tbuckley/cabot-search huggingface dataset:
Abstract 14088: Advanced Chronic Kidney Disease Is Associated With Increased LGE-MRI Quantified Atrial Fibrosis in Patients with Atrial Fibrillation
Authors: Michel Barakat, Nazem Akoum, Nathan Burgon, Thom Haslam, Kavitha Damal, Nassir Marrouche
Journal: Circulation (2011)

Background:  Chronic kidney disease (CKD) is independently associated with worse cardiovascular outcomes as well as a higher prevalence of atrial fibrillation (AF). We sought to examine the correlation of CKD with atrial fibrosis assessed using late gadolinium-enhancement MRI (LGE-MRI).   Methods:  Four hundred and ninety six patients with AF, presenting for catheter ablation at the University of Utah were included in this study. All patients underwent LGE-MRI prior to catheter ablation of AF. Left atrial fibrosis (LA) was quantified using the Coreview software and was reported as a proportion of the LA wall volume. Creatinine clearance (CrCl) was calculated using the Cockroft-Gault equation. Patients were classified into CKD class I if their CrCl≥90, CKD class 2 if 60   Results:  The average CrCl was 94.1±40.4% for the entire cohort. 235 patients (47.7%) fell into CKD class 1, followed by CKD class 2 (172 patients, 34.9%); CKD class 3 (83 patients, 16.8%) and CKD class 4 (3 patients, 0.6%). No patients in this cohort had CKD stage 5 as this constituted a contraindication to gadolinium contrast administration. The mean LA fibrosis of the cohort was 16.2±10.7%. The mean LA fibrosis was comparable in CKD stages 1 and 2 (15.6±10.5% vs 15.5±10.3%, p=0.95). Compared to CKD class 1 and 2, LA fibrosis was significantly higher in CKD stage 3 (18.6±11.6%; p=0.03), and CKD stage 4 (25.2±13.2%; p=0.03) (figure). Atrial fibrosis was the strongest predictor of AF recurrence post ablation (HR 1.05 per % increase, p   Conclusions:  Advanced stages of chronic kidney disease are associated with a significantly increased burden of left atrial fibrosis in patients with atrial fibrillation. This finding has potential management implications of the arrhythmia in this subgroup.
The Art of Compounding. A Text-book for Students and a Reference Book for Pharmacists at the Prescription Counter.
Authors: Wilbur Lincoln Scoville
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Liver metastatic growth of human tumor cells in Rag2-/-;γc-/- mice
Authors: Carla De Giovanni, Giordano Nicoletti, Lorena Landuzzi, Stefania Croci, Arianna Palladini, Agnese Antognoli, Elisa Resca, Annalisa Murgo, Patrizia Nanni, Pier-Luigi Lollini
Journal: Cancer Research (2007)

AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

3851 

BALB-Rag2-/-;γc-/- mice, developed by the Central Institute for Experimental Animals (CIEA, Kawasaki, Japan), lack the expression of both the recombinase activating gene 2 (Rag2) and the common cytokine receptor γ chain (γc) and show a complete absence of T, B and NK responses. These mice should accept xenotransplants of both immune and nonimmune cells much better than other immunodeprived mice such as nude or SCID mice, which retain NK activity.

We took advantage of BALB-Rag2-/-;γc-/- mice to investigate the metastatic potential of several human tumor cell lines of different histotypes (rhabdomyosarcoma, Ewing’s sarcoma, osteosarcoma, breast and colorectal carcinoma cell lines). Metastases were induced by intravenous cell injection. The different cell lines showed unique metastatic patterns. Most human tumor cell lines were able to metastasize to lungs, but strongly differed in metastases incidence and number. Liver metastasization was even more specific: most sarcoma cell lines gave rise to multiple huge liver metastatic lesions, in some cases in the absence of lung metastases. Parallel experiments in nude mice with NK depletion (through anti-asialo treatment) failed to show liver metastases. Therefore BALB-Rag2-/-;γc-/- mice can be a highly effective model to study liver metastases of human tumor cells, and could allow to evaluate new therapeutic treatments.
Abstract 173: Microcirculatory Alterations After Cardiac Arrest Are Worse With Longer Downtime and Are Not detected by Measurement of Blood Pressure
Authors: Manuel Boller, Joseph M Katz, Lance B Becker
Journal: Circulation (2010)

Aim: Abnormalities in microvascular blood flow are of increasing interest during the post-resuscitation phase following cardiac arrest because they may not be detected by macrocirculatory indices, ...
The Problems and Prospects of LSD
Authors: J. Thomas Ungerleider
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Socialization of Medicine
Authors: Edith M. Phelps
Journal: BMJ (1908)

The H. W. Wilson Company has for some years prepared under the general title "The Reference Shelf" a series of reference and guide books for debaters on various topics. The present volume on socialized medicine provides two excellent briefs for the affirmative and negative sides of the subject, a fairly extensive but well selected bibliography, definitions to guide debaters in their understanding of the topic to be discussed, and then a number of reprints of various articles by physicians, social workers and economists on this subject. These articles are divided into general discussions, affirmative discussion and negative references. It is exceedingly interesting to find the names of John A. Kingsbury and Rufus Rorem among those whose articles are put on the negative side. What a gnashing of teeth there will be when these gentlemen find where they have been located! Presumably Mr. Kingsbury was put into the negative side because
Between Two Worlds: The Memoirs of a Physician
Authors: Benjamin Lee Gordon
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Geographical variations in the impact of atopy on asthma in the Europeean Community Respiratory Health Study(ECRHS)
Authors: J Sunyer, D Jarvis, J Pekkanen, S Chinn, Christer Janson, B Leynaert, C Luczynska, R Garcia-Esteban, P Burney, JM Antó
Journal: Journal of Allergy and Clinical Immunology (2004)
Abstract 16415: Patterns of Atrial Fibrillation and Treatment Strategies Vary According to Provider Specialty Across Community Practice Settings: Findings From the ORBIT-AF Registry
Authors: Jonathan P Piccini, Dajuanicia N Holmes, Donna M Ollis, Elizabeth S Fraulo, Laine Thomas, Jack E Ansell, Gregg C Fonarow, Bernard J Gersh, Alan S Go, Elaine M Hylek, Peter R Kowey, Kenneth W Mahaffey, Renato D Lopes, Roger M Mills, Eric D Peterson
Journal: Circulation (2011)

Background: The numbers of patients with atrial fibrillation (AF) is growing rapidly, yet there are limited data on variation in AF presentation and treatment across various practice settings. Meth...
Industry pays women doctors less for research, speaking, and meals, US study finds
Authors: M. McCarthy
Journal: BMJ (2015)

Female physicians who have financial ties with the biomedical and pharmaceutical industry are paid significantly less than their male counterparts, a new US study has found.1 Overall, even after controlling for such factors as specialty, age, and institutional reputation, female physicians received about $3600 (£2270; €3160) a year less than male physicians, the study found. The disparities in payment were seen in almost every kind of industry tie, including money …
Medical Education Today: Its Aims, Problems and Trends
Authors: Joseph C. Hinsey, Dean F. Smiley
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II study of S-1 plus irinotecan and oxaliplatin for refractory, heavily treated metastatic colorectal cancer
Authors: S. Y. Kim, Y. S. Hong, H. S. Han, S. B. Lim, H. S. Choi, S. Y. Jeong, J. Y. Jeong, C. W. Hong, D. K. Sohn, K. H. Jung
Journal: Journal of Clinical Oncology (2008)

15116 Background: Three-drug combination of fluoropyrimidine, irinotecan and oxaliplatin is known to be active for metastatic colorectal cancer (mCRC). In vitro synergy has been reported with each drug, thus combination of all 3-drug may overcome refractoriness to each other. We had performed phase I study to determine doses of phase II study of S-1 plus irinotecan and oxaliplatin (TIROX) for untreated mCRC, favorable responses were also observed in heavily-treated mCRC in phase I. We performed a phase II study of TIROX to evaluate efficacy and safety in refractory, heavily treated mCRC patients (pts) with no further treatment option. Methods: Pts with refractory to all of 3 drugs, age ≥ 18 yrs, PS 0–2, ≥ 1 measurable lesion(s) and adequate organ functions were eligible. S-1 was given 40 mg/m2 twice a day on D1–14, oxaliplatin 85 mg/m2 and irinotecan 150 mg/m2 on D1 every 3 weeks. The primary endpoint was overall response rate (ORR) and secondary endpoints were progression free survival (PFS) and overall survival (OS). Results: Between Mar 2007 and Nov 2007, 19 pts (of 18 planned) were enrolled; median age 50 yrs; M/F 12/7; PS 0/1/2 5/13/1; colon/rectum 11/8. Median OS from initial diagnosis of mCRC to the TIROX was 20.9 months (mo) and G1 sensory neuropathy was noted in 15 pts at baseline. TIROX was their 3rd line regimen in 3 (15.8%), 4th in 13 (57.9%) and ≥ 5th in 3 pts (15.8%). Bevacizumab and cetuximab was exposed previously to 4 and 7 pts, respectively. By intent-to-treat analysis, ORR was 21.1% (95% CI, 8.7 - 43.7) and disease control rate was 52.6% (95% CI 31.5 - 72.8) with 4 PRs and 6 SDs. The median duration of disease control was 4.3 mo (95% CI 1.7–6.9). Median PFS was 2.6 mo (95% CI 2.2 - 2.9) and median OS was not reached with median FU of 7.5 mo. G3/4 toxicities per pt included neutropenia (5, 26.3%), leucopenia (3, 15.8%), febrile neutropenia (2, 10.5%), thrombocytopenia (1, 5.3%), diarrhea (2, 10.5%) and fatigue (2, 10.5%). Conclusions: TIROX seemed to be feasible for refractory, heavily-treated mCRC pts. Combination of previously exposed agents may have activity against refractory mCRC and could be an alternative for pts with good PS but no further treatment options. No significant financial relationships to disclose.
Fundamentals of Clinical Hematology.
Authors: Jerry L. Spivak, Edward R. Eichner
Journal: Annals of Internal Medicine (1977)

Hematopoietic stem cells iron deficiency macrocytic anemia hemoglobinopathies and thalassemias heolytic anemia normocytic anemia porphyrias, lead poisoning, and sideroblastic anemias erythrocytosis and polycythemia neutrophils monocytes and macrophages lymphocytes the spleen leukemia non-Hodgkin lymphoma Hodgkin disease plasma cell dyscrasias platelets coagulation factors antithrombotic therapy transfusion medicine the management of bone marrow suppression bone marrow transplantation nuclear medicine.
The Impact Of Subclonal Versus Clonal Novel Recurrent Mutations On Treatment Outcome In Previously Untreated High Risk CLL Patients: Results From The HOVON68 Trial
Authors: Doreen te Raa, Arnon P. Kater, Wendim Ghidey Alemayehu, Alexander Jethwa, Jennifer Hullein, Eric Eldering, Tatjana Stankovic, Thorsten Zenz, Christian H Geisler, Marinus H.J. Van Oers
Journal: Blood (2013)
Breathing Disorders of Sleep.
Authors: Walter T. McNicholas, Eliot A. Phillipson.
Journal: Annals of Internal Medicine (1987)

Chapter Part One Introduction 1 Impact of Sleep on Respiration J Dempsey 2 Assessment of the Sleepy Patient J Krieger Part Two Obstructive Sleep Apnoea 3 Epidemiology of Obstructive Sleep Apnea T Young 4 Athogenesis of Obstructive Sleep Apnea D White 5 Clinical Features of Sleep Apnea W Flemons 6 Investigation and Diagnosis of Suspected Sleep Apnea K Strohl Part Three Management 7 Management Options for Snoring and Obstructive Sleep Apnea P Levy and J-L Pepin 8 Nasal Continuous Positive Airway Pressure C Sullivan 9 Surgical Management A Sher 10 Pharmacological Therapy of Sleep Apnea J Hedner 11 Oral Devices for Snoring and Obstructive Sleep Apnea J Fleetham 12 Significance and Management of Snoring without Sleep Apnea V Hoffstein Part Four Complications 13 Neuropsychiatric/Behavioural C Guileminault 14 Cardiovascular Complications of Sleep Apnea J Stradling 15 Hormonal and Metabolic Aspects of Sleep Apnea R Grunstein 16 Morbidity, Mortality and Public Health Implications of Sleep Apnea S Redline Part Five Central Sleep Apnea 17 Hypoventilation Disorders/Hyprcapnic CSA E Phillipson 18 Normo/Hypocapnic CSA T Douglas Bradley Part Six Sleep Apnea in the Young and Elderly 19 Sleep Apnea in Infants and Children C Gaultier 20 The Elderly S Ancoli-Israel Part Seven Sleep in Other Respiratory Disorders 21 Nocturnal Asthma N Douglas 22 COPD W McNicholas 23 Neuromuscular and Chest Wall Disorders R Grunstein 24 Instertitial Lung Disease, Cystic Fibrosis and Other Respiratory Disorders P Calverley
Die Schlafstörungen und ihre Behandlung.
Authors: L. E. Bregman
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is there a need for anti-rabies vaccine and immunoglobulins rationing in Europe?
Authors: H Bourhy, M Goudal, A Mailles, M Sadkowska-Todys, L Dacheux, H Zeller
Journal: Eurosurveillance (2009)

Rabies is a lethal encephalitis caused by a lyssavirus and transmitted from animals to humans via bite wound, scratch wound, or licking of mucous membranes. It is preventable by timely administration of post-exposure prophylaxis (PEP) consisting of four or five doses of rabies vaccine combined, in the most severe cases of exposures, with anti-rabies immunoglobulin (RIG). Although the rabies incidence in humans remains low, rabies is still present in some European countries. Moreover, rabid animals imported from enzootic areas are reported every year in rabies-free areas. These importations threaten the rabies-free status of terrestrial animals in western European countries and challenge the public health surveillance system and the health structures responsible for rabies prophylaxis and control. The importations frequently result in the prescription of a large number of PEP including RIG, especially in western European countries. The situation is inverted in some central and eastern European countries where RIG is underprescribed. Only a limited number of rabies vaccines and particularly of RIG are licensed for use in Europe. Their availability is also limited, a situation that may become worse in the future. It therefore seems important to study the possibility of comparing and unifying national PEP guidelines in Europe, if needed, and to generate effective solutions in the event of a shortage of anti-rabies biological products and RIG in particular, such as rationing these products.
Abstract 223: End Tidal Carbon Dioxide Levels Predict Cardiac Arrest
Authors: Harish Manyam, Prashan Thiagarajah, Gauravkumar Patel, Russell French, Diane Vido, Siresha Chaluvadi, Marvin Balaan
Journal: Circulation (2010)

Introduction: End tidal carbon dioxide (CO2) correlates with cardiac output during cardiopulmonary resuscitation in cardiac arrest patients. Increasing CO2 during CPR can also indicate the return o...
Taschenbuch der Frauenheilkunde.
Authors: Alfred Koblanck
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE TOLERANCE OF NORMAL SUBJECTS TO LEVULOS E
Authors: Norman Jolliffe
Journal: Journal of Clinical Investigation (1930)

MacLean and de Wesselow (1) examined the type of blood sugar curves obtained in normal and diabetic subjects.They suggest that such curves rise very slowly or fail to rise during the second thirty minute period following administration of sugar by mouth, due to stimulation of the glycogen storage mechanism which abstracts the sugar from the blood more quickly than it enters.They believe that this dormant glycogen-forming function of the liver does not begin to act until the sugar concentration approaches 140 mgm.per cent.That the glycogen-storing function is stimulated by hyperglycemic levels is supported by Foster (2).He found that oral administration of glucose, when the concentration of the blood sugar is falling, results in little or no increase in blood sugar.This observation of Foster has been amply confirmed, especially by the work of du Vigneaud and Karr (3) and later by Lennox and Bellinger (4).That there is a relation between the fasting blood sugar level and its rise above the fasting level following the administration of levulose by mouth seems borne out by this investigation.This relationship is intimately concerned with the mechanism by which the normal subject maintains his fairly constant blood sugar level as recently shown by Jonas and his associates (5), Trimble and Maddock (6) and Sweeney (7).They show that the normal subject maintains a blood sugar almost invariably between 80 and 140 mgm.per cent during such diverse activities as rest, sleep, mild exercise, work, and eating.Schirokauer (8) was the first investigator who studied the rise in blood sugar following the oral administration of levulose.He found